Hormonal
Rosiglitazone treatment reverses elevated malonyl-CoA levels, restores fatty acid oxidation, and improves insulin sensitivity in type 2 diabetic subjects.
For type 2 diabetics, rosiglitazone (4mg twice daily for 3 months) was shown to normalize malonyl-CoA levels and restore fatty acid oxidation. This suggests that pharmacological intervention can correct specific muscle metabolic defects associated with insulin resistance.
All of these abnormalities in the type 2 diabetic group were reversed by rosiglitazone treatment.
Why this rating
Randomized controlled trial design (implied by treatment group vs non-treatment) with human subjects.
Source
Increased Malonyl-CoA Levels in Muscle From Obese and Type 2 Diabetic Subjects Lead to Decreased Fatty Acid Oxidation and Increased Lipogenesis; Thiazolidinedione Treatment Reverses These Defects
Gautam Bandyopadhyay et al. · Diabetes · 2006
DOI 10.2337/db06-0062
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →